Pathology and Immunology of COVID-19
Since the first case of COVID-19 was reported from Wuhan, China in December 2019, SARS-CoV-2 has been spreading globally and has become major public health concern. At present, development of specific treatment for COVID-19 is in progress and several countermeasures have been subjected to clinical trials. However, efficacy of these countermeasures is limited. For development of effective medicines or vaccines against infectious diseases, it is mandatory to elucidate its etiology and pathogenesis by means of pathological analysis. Pathological studies revealed that the COVID-19 mainly affects respiratory tracts although other organs are also involved. In addition, immunological studies demonstrated that host immune response may exacerbates COVID-19 through systemic inflammation. In this review, we would like to overview pathology and immunology of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Uirusu - 70(2020), 2 vom: 01., Seite 167-174 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Iida, Shun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 21.09.2021 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2222/jsv.70.167 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330867970 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330867970 | ||
| 003 | DE-627 | ||
| 005 | 20231225212220.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.2222/jsv.70.167 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM330867970 | ||
| 035 | |a (NLM)34544931 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Iida, Shun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pathology and Immunology of COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Since the first case of COVID-19 was reported from Wuhan, China in December 2019, SARS-CoV-2 has been spreading globally and has become major public health concern. At present, development of specific treatment for COVID-19 is in progress and several countermeasures have been subjected to clinical trials. However, efficacy of these countermeasures is limited. For development of effective medicines or vaccines against infectious diseases, it is mandatory to elucidate its etiology and pathogenesis by means of pathological analysis. Pathological studies revealed that the COVID-19 mainly affects respiratory tracts although other organs are also involved. In addition, immunological studies demonstrated that host immune response may exacerbates COVID-19 through systemic inflammation. In this review, we would like to overview pathology and immunology of COVID-19 | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Suzuki, Tadaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Uirusu |d 1972 |g 70(2020), 2 vom: 01., Seite 167-174 |w (DE-627)NLM000245429 |x 0042-6857 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2020 |g number:2 |g day:01 |g pages:167-174 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2222/jsv.70.167 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2020 |e 2 |b 01 |h 167-174 | ||